ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard
Boston, MA 02210
United States
475-230-2596
http://www.alexion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,525

Key Executives

NameTitlePayExercisedYear Born
Dr. Ludwig N. HantsonCEO & DirectorN/AN/A1963
Mr. Paul J. ClancyExec. VP & CFON/AN/A1962
Mr. Brian GoffExec. VP & Chief Commercial OfficerN/AN/A1969
Mr. Daniel A. Bazarko CPAChief Accounting Officer & Sr. VPN/AN/AN/A
Ms. Indrani M. Lall FranchiniExec. VP & Chief Compliance OfficerN/AN/A1972
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Corporate Governance

Alexion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.